Ireneusz Walaszek

Dr. Ireneusz Walaszek


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JKJan Korbecki
Jan Korbecki
MBMateusz Bosiacki
Mateusz Bosiacki
MPMaciej Pilarczyk
Maciej Pilarczyk
MKMarcin Kot
Marcin Kot
PDPiotr A Defort
Piotr A Defort
IBIrena Baranowska-Bosiacka
Irena Baranowska-Bosiacka
CXCL1 (Gro-α, MGSA) is a chemokine functionally similar to CXCL8/IL-8, as both activate the same receptor, CXCR2. CXCL1 levels are frequently elevated in tumors compared to healthy tissue, where they play a key role in promoting cancer cell migration, angiogenesis, and neutrophil recruitment. While the involvement of CXCL1 in tumor progression is well established, its relevance to cancer therapy remains underexplored. This review examines the therapeutic potential of targeting CXCL1 and its receptor, CXCR2, in cancer treatment. It discusses anti-CXCL1 antibodies and CXCR2 antagonists, including AZD5069, SB225002, SCH-479833, navarixin/SCH-527123, ladarixin/DF2156A, and reparixin, as well as strategies to enhance CXCR2 expression in lymphocytes during adoptive cell therapy to improve immunotherapy outcomes. Particular attention is given to the role of CXCL1 in treatment resistance, including resistance to chemotherapy, radiotherapy, and anti-angiogenic therapy. Cancer therapies often upregulate CXCL1 expression, which in turn drives treatment resistance. Additionally, this review explores the contribution of CXCL1 to therapy-induced side effects, such as chemotherapy-induced metastasis, neuropathy, nephrotoxicity, diarrhea, and cardiotoxicity. CXCR2 inhibitors are well tolerated by patients in clinical trials. However, the limited number of studies evaluating these agents in combination with standard chemotherapy precludes any definitive conclusions.

27 February 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Kamila RachubińskaKamila Rachubińska
Kamila Rachubińska
Anna Maria CybulskaAnna Maria Cybulska
Anna Maria Cybulska
ASAleksandra Szylińska
Aleksandra Szylińska
Ewa KupcewiczEwa Kupcewicz
Ewa Kupcewicz
DĆDorota Halina Ćwiek
Dorota Halina Ćwiek
EGElzbieta Grochans
Elzbieta Grochans
(1) Background: This study aimed to establish the connection between depressiveness, workaholism, eating disorders, and personality traits, according to the five-point model called the Big Five, in women with a risk of compulsive buying disorder. (2) Methods: The study was conducted on 556 Polish women from the West Pomeranian Voivodeship. The study employed the diagnostic survey method using a questionnaire technique including Personality Inventory NEO-FFI, the Buying Behaviour Scale, the Beck Depression Inventory I-II, the Three-Factor Eating Questionnaire, and a self-questionnaire. (3) Results: The analysis revealed the risk of compulsive buying being accompanied by a higher median score for depressiveness, neuroticism, Cognitive Restraint of Eating, Uncontrolled Eating, and a risk of workaholism. A lower score in the respondents in the compulsive buying risk group was observed in an assessment of agreeableness and conscientiousness. Work addiction was exhibited by 26% of people with compulsive buying disorder vs. 12% of people without it. (4) Conclusion: This study found that a high risk of compulsive buying disorder is accompanied by a high risk of moderate depressiveness, neuroticism, Cognitive Restraint of Eating, Uncontrolled Eating, and workaholism. It also confirmed the view that compulsive buying is a behavioural addiction which is a consequence of ineffective coping and being dissatisfied with one’s social life.

21 June 2024 in Children
Verified
Journal Article
Open access
PDF file
KGKaja Giżewska-Kacprzak
Kaja Giżewska-Kacprzak
MŚMaximilian Śliwiński
Maximilian Śliwiński
KNKarol Nicieja
Karol Nicieja
LBLidia Babiak-Choroszczak
Lidia Babiak-Choroszczak
IWIreneusz Walaszek
Ireneusz Walaszek
Macrodactyly is a rare congenital limb difference manifesting as an overgrowth of one or more fingers or toes. The pathological process affects all tissues of the ray in the hand or foot. The enlargement can significantly alter the limb’s appearance and impair its function. The role of a pediatrician is to distinguish isolated macrodactyly from syndromic conditions (including PIK3CA-Related Overgrowth Spectrum) or mimicking conditions to enable early interdisciplinary consultation and treatment planning. The psychological stigma associated with this often disfiguring condition necessitates support for patients and their family. We present a practical guide for physicians who might be the first to raise suspicion of macrodactyly and initiate further diagnostics to achieve adequate treatment and support for children and caregivers.

Verified
Journal Article
Open access
PDF file
JKJan Korbecki
Jan Korbecki
MBMateusz Bosiacki
Mateusz Bosiacki
EDEdyta Anna Dzięciołowska-Baran
Edyta Anna Dzięciołowska-Baran
PPPatrycja Pawlik
Patrycja Pawlik
MLMichał Lubkowski
Michał Lubkowski
KBKatarzyna Barczak
Katarzyna Barczak
Chemokine CXCL1, also known as Gro-α and MGSA, a ligand of CXCR2, is the best-known CXC chemokine in cancer processes, after CXCL8/IL-8 and CXCL12/SDF-1. This paper is the first review on the role of CXCL1 in general molecular processes associated with cancer. It provides a comprehensive overview that allows for an in-depth understanding of the importance of CXCL1 in tumor-related processes. In this review, however, we did not address the clinical aspects of CXCL1, as these were discussed in our previous review articles. The present paper focuses on the involvement of CXCL1 in cancer processes such as proliferation, cancer stem cell (CSC) function, senescence, angiogenesis, lymphangiogenesis, migration and metastasis, and effects on tumor-associated cells such as neutrophils, tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), mesenchymal stem cells (MSCs), and cancer-associated fibroblasts (CAFs). It also describes the significance of CXCL1 in cancer-associated diseases such as cancer cachexia, cancer-associated immunodeficiency, neuroinflammatory-mediated affective-like behaviors, bone cancer pain, and acute kidney injury. We also present the effects of obesity on CXCL1-related cancer processes.

12 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Marta NowakMarta Nowak
Marta Nowak
Anna Maria CybulskaAnna Maria Cybulska
Anna Maria Cybulska
DSDaria Schneider-Matyka
Daria Schneider-Matyka
EGElzbieta Grochans
Elzbieta Grochans
IWIreneusz Walaszek
Ireneusz Walaszek
Kamila RachubińskaKamila Rachubińska
Kamila Rachubińska
Background: Age-related macular degeneration (AMD) is a progressive, chronic eye disease with no permanent cure currently available. Symptoms of the disease, including distorted and blurred vision and gradual loss of central vision, significantly aggravate patients’ daily functioning. The purpose of this study was to assess the acceptance of the disease among patients diagnosed with neovascular age-related macular degeneration before treatment and after receiving seven intravitreal injections and to determine how it was related to the values of visual parameters. Methods: This survey-based study was carried out using the author’s questionnaire and a standardized research tool, the Acceptance of Illness Scale (AIS). It also involved the analysis of the patients’ medical records. Results: The study included 121 patients (121 eyes), including 60 women and 61 men. The age range of the participants was 51–90 years. The mean and median age of the participants was 75 years. After undergoing a series of intravitreal injections, statistically significant improvements were observed in the degree of illness acceptance according to the AIS score. Data analysis revealed that the degree of disease acceptance was significantly related to visual acuity and contrast sensitivity. Conclusions: The acceptance of the disease among the study participants from the beginning of the therapy until receiving a series of seven intravitreal injections was at an average level. Acceptance of the disease was better before the beginning of the therapy, due to higher values of corrected visual acuity, and after the therapy, because of higher values of contrast sensitivity and corrected visual acuity.

Verified
Journal Article
Open access
PDF file
IWIreneusz Walaszek
Ireneusz Walaszek
DSDaria Schneider-Matyka
Daria Schneider-Matyka
MBMateusz Bosiacki
Mateusz Bosiacki
SGSzymon Grochans
Szymon Grochans
KGKaja Giżewska-Kacprzak
Kaja Giżewska-Kacprzak
Kamila RachubińskaKamila Rachubińska
Kamila Rachubińska
Upper limb disorders, including carpal tunnel syndrome (CTS), are a common cause of pain, functional limitations, and reduced quality of life. Increasing attention has been directed toward the role of inflammatory and angiogenic mediators in the pathophysiology of CTS and their potential relationship with patient-reported functional outcomes. The aim of this study was to evaluate selected cytokines as potential markers of upper limb disability assessed using the Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. This cross-sectional study included 55 patients with idiopathic CTS referred for surgical treatment. Functional impairment was assessed using the DASH questionnaire, and concentrations of selected inflammatory and angiogenic mediators—IL-4, IL-6, MCP-1, TNF-α, VEGF, and fraktalkine—were measured in synovial tissue samples; these markers were selected based on their established roles in inflammation, angiogenesis, and nociceptive modulation relevant to CTS pathophysiology. VEGF was identified as a significant predictor of DASH category (p = 0.032), with higher concentrations associated with a lower likelihood of severe upper limb dysfunction. In contrast, higher TNF-α levels were associated with an increased risk of severe disability (p = 0.031). Other cytokines did not demonstrate significant associations with functional impairment. These findings suggest that selected inflammatory and angiogenic mediators were associated with the severity of functional disability in CTS and warrant investigation in prospective longitudinal studies to clarify their potential role alongside patient-reported outcome measures.